Document is current
Any future updates will be listed below
-
Authors
Takahashi, Naoto https://orcid.org/0000-0002-6758-3787
Kimura, Shinya
Matsuki, Eri
Ono, Takaaki
Doki, Noriko
Iino, Masaki
Sawa, Masashi
Saburi, Yoshio
Murai, Kazunori
Fujimaki, Katsumichi
Kurahashi, Shingo
Iriyama, Noriyoshi
Onaka, Takashi
Sakaida, Emiko
Yoshida, Chikashi
Sato, Keijiro
Miyamoto, Toshihiro
Takaku, Tomoiku
Shiratsuchi, Motoaki
Kimura, Fumihiko
Katagiri, Seiichiro
Yamamoto, Matsuo
Saito, Akiko M.
Kiyoi, Hitoshi
Matsumura, Itaru
-
Funding
Funding for this research was provided by:
Japanese Society of Hematology
Akita University
- License Information
-
More Information
Article History
Received: 3 December 2025
Revised: 10 February 2026
Accepted: 13 February 2026
First Online: 1 March 2026
Declarations
:
: Naoto Takahashi received consultancy fees (including expert testimony), research funding, honoraria from Novartis Pharma KK, consultancy fees, research funding, honoraria from Otsuka Pharmaceutical Co., Ltd., honoraria from Pfizer Japan Inc., and research funding from the Japanese Society of Hematology for the present study. Shinya Kimura received research funding and honoraria from Bristol-Myers Squibb; Otsuka Pharmaceutical Co., Ltd.; Novartis Pharma KK; and Pfizer Japan, Inc. Eri Matsuki received honoraria from Pfizer Japan Inc., Otsuka Pharmaceutical Co., Ltd., Bristol-Myers Squibb, and Novartis Pharma KK. Takaaki Ono received honoraria from Pfizer Japan Inc. and Novartis Pharma KK. Katsumichi Fujimaki received honoraria from Otsuka Pharmaceutical Co., Ltd. Noriyoshi Iriyama received honoraria from Otsuka Pharmaceutical Co., Ltd., Novartis Pharma KK, Pfizer Japan Inc., and Bristol-Myers Squibb. Chikashi Yoshida received honoraria from Otsuka Pharmaceutical Co., Ltd., Novartis Pharma KK, and Pfizer Japan Inc.; consultancy fees (including expert testimony) from Novartis Pharma KK; and research funding from Bristol-Myers Squibb. Tomoiku Takaku received honoraria from Novartis Pharma KK and Otsuka Pharmaceutical Co., Ltd., and he is the editor of the International Journal of Hematology. Itaru Matsumura received research funding and honoraria from Otsuka Pharmaceutical Co., Ltd., and honoraria from Bristol-Myers Squibb, Novartis Pharma KK, and Pfizer Japan Inc. The other authors declare no conflicts of interest.
